#NewAseBioMember | 'AseBio is the meeting point of the Spanish biotechnology ecosystem'

AseBio. What does your company's work bring to the table and what is its strength?

Pedro Bernardo Martín-Borregón. Neural Omega combines scientific research with clinical application in autoimmune diseases. Our greatest strength is the unique intersection between medicine, bioinformatics, and artificial intelligence: we develop proprietary omics analysis technology whilst maintaining the clinical perspective of those working directly with patients. This allows us to translate real medical needs into tools for both researchers and patients.

AseBio. What is AseBio for you?

Pedro Bernardo Martín-Borregón. AseBio is the meeting point of the Spanish biotechnology ecosystem. For us, it represents the opportunity to connect with companies, research centres, and investors who share our vision of driving biomedical innovation in Spain. It's also a source of collective knowledge from which we want to learn, particularly regarding regulatory aspects and sector best practices.

AseBio. When did you first hear about AseBio?

Pedro Bernardo Martín-Borregón. During my medical training, whilst researching the Spanish biotech ecosystem and evaluating where to establish Neural Omega. AseBio stood out as the central organisation representing and giving visibility to the national biotechnology sector.

AseBio. What do you expect from being part of an association like AseBio?

Pedro Bernardo Martín-Borregón. We fundamentally expect to establish strategic connections with other players in the biotech ecosystem; to learn from the sector's collective experience in areas such as regulation, funding, and best practices; and to gain credibility and visibility as a serious company in the sector, which is essential for future collaborations and research projects.

AseBio. What is the biggest challenge facing the biotech sector or your company?

Pedro Bernardo Martín-Borregón. For Neural Omega, the biggest challenge is balancing scientific rigour with development speed in a sector where both are critical. At the Spanish biotech sector level, I believe the main challenge is attracting more specialised and patient capital that understands the long development cycles in biotechnology, especially for early-stage companies with deep technology.